Novartis logo 2020 ASCO Annual MeetingHave a Question?

This site is for health care professionals only.

Novartis Presentations

See below for our abstracts.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.


This compilation of presentations is for educational purposes only. Copies of posters are for personal use only and may not be reproduced without permission from the author of the poster. Linked materials are accessible beginning on Friday, May 29th. The links below will remain active for a limited time.

Breast Cancer

Alpelisib

Abstract # 1006 - Oral

Alpelisib (ALP) + Fulvestrant (FUL) in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor-2-Negative (HER2–) Advanced Breast Cancer (ABC) Previously Treated With Cyclin-Dependent Kinase Inhibitor (CDKi) + Aromatase Inhibitor (AI): BYLieve Study Results

Lead Author: Rugo

View Abstract

Alpelisib

Abstract # 1069 - Poster

PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/ human endocrine receptor negative (HER2–) metastatic breast cancer (mBC): a meta-analysis of published clinical trials

Lead Author: Signorovitch

View Abstract

Letrozole

Abstract # 1534 - Poster

Five-year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial

Lead Author: Pujol

View Abstract

Pazopanib

Abstract # 1068 - Poster

Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC)

Lead Author: Gumusay

View Abstract

Ribociclib

Abstract # 1054 - Poster

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and -7 (ML-7) trials

Lead Author: Yardley

View Abstract

Ribociclib

Abstract # 1055 - Poster

Updated Results From the Phase IIIb COMPLEEMENT-1 Study of Ribociclib (RIB) Plus Letrozole (LET) in the Treatment of HR+, HER2– Advanced Breast Cancer (ABC)

Lead Author: De Laurentiis

View Abstract

Hematology

Nilotinib

Abstract # 7548 - Poster

Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice after Guideline Updates

Lead Author: Atallah

View Abstract

Tisagenlecleucel

Abstract # 10518 - Poster Discussion

Tisagenlecleucel for Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia (ALL): B2001X Study Focusing on Prior Exposure to Blinatumomab (BLINA) and Inotuzumab (INO)

Lead Author: Krueger

View Abstract

Lung Cancer

Canakinumab

Abstract # TPS9075 - Poster

CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab versus placebo as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC)

Lead Author: Garon

View Abstract

Canakinumab

Abstract # TPS9626 - Poster

Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N

Lead Author: Mok

View Abstract

Capmatinib

Abstract # 9509 - Oral

Shell/LBA: Capmatinib in patients (pts) with high MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study

Lead Author: Wolf

View Abstract

Capmatinib

Abstract # 9520 - Poster Discussion

Shell/LBA: Capmatinib in patients (pts) with METex14-mutated or high MET-amplified advanced non-small cell lung cancer (NSCLC): results from Cohort 6 of the phase 2 GEOMETRY mono-1 study

Lead Author: Groen

View Abstract

Ceritinib

Abstract # 10505 - Oral

Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK)

Lead Author: Schulte

View Abstract

Ceritinib

Abstract # 3520 - Poster

An open label, multi-center, phase 2 study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10)

Lead Author: Moreno

View Abstract

Dabrafenib + Trametinib

Abstract # 9593 - Poster

Updated Overall Survival (OS) and Genomic Analysis from a Single-Arm Phase 2 Study of Dabrafenib (D) + Trametinib (T) in Patients (pts) with BRAF V600E Mutant (Mut) Metastatic Non-small Cell Lung Cancer (NSCLC)

Lead Author: Planchard

View Abstract

Nazartinib

Abstract # 9574 - Poster

Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): updated phase II results

Lead Author: Tan

View Abstract

Melanoma & Pediatric Glioma

Dabrafenib + Trametinib

Abstract # 10001 - Oral

Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: 5-year analysis of COMBI-AD

Lead Author: Hauschild

View Abstract

Dabrafenib + Trametinib

Abstract # 10028 - Poster

The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: efficacy and safety findings from Parts 1 and 2 of the Phase III COMBI-i trial

Lead Author: Long

View Abstract

Dabrafenib + Trametinib

Abstract # 10506 - Oral

Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: safety and efficacy results

Lead Author: Geoerger

View Abstract

Dabrafenib + Trametinib + Spartalizumab

Abstract # 10034 - Poster

Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma

Lead Author: Dummer

View Abstract

Soft Tissue Sarcoma

Pazopanib

Abstract # 11515 - Poster Discussion

A randomized phase II study of gemcitabine (G) alone or with pazopanib (P) in refractory soft tissue sarcoma (STS)

Lead Author: Ryan

View Abstract

Other Solid Tumors

LTT462

Abstract # 3640 - Poster

Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations

Lead Author: Janku

View Abstract

5/20 G-PIP-1230667